Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Scripps Tumorgraft Study

This study has been completed.
Information provided by (Responsible Party):
Eric Topol, MD, Scripps Translational Science Institute Identifier:
First received: November 6, 2012
Last updated: April 1, 2015
Last verified: April 2015
Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.

Solid Tumor Malignancy or Hematologic Malignancy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Scripps Tumorgraft Study

Further study details as provided by Eric Topol, MD, Scripps Translational Science Institute:

Primary Outcome Measures:
  • Facilitate the development of individualized tumorgraft models for many different types of cancer. [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
Blood and tissue samples

Enrollment: 11
Study Start Date: November 2012
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Cancer Diagnosis


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adults with a solid tumor malignancy or a hematologic malignancy

Inclusion Criteria:

  • Age 21 or over
  • diagnosis of a solid tumor malignancy, either resectable or metastatic or a hematologic malignancy
  • cognitively and emotionally able to give informed consent

Exclusion Criteria:

  • Under age 21
  • Not cognitively or emotionally able to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01726699

United States, California
Scripps Translational Science Institute
La Jolla, California, United States, 92037
Sponsors and Collaborators
Scripps Translational Science Institute
Principal Investigator: Laura Goetz, MD Director, Applied Genetic Epidemiology
  More Information

Responsible Party: Eric Topol, MD, Director, Applied Genetic Epidemiology, Scripps Translational Science Institute Identifier: NCT01726699     History of Changes
Other Study ID Numbers: 12-6011
Study First Received: November 6, 2012
Last Updated: April 1, 2015

Additional relevant MeSH terms:
Neoplasms processed this record on May 25, 2017